Webinar Presenter
Intergenerational Effects of Adversity on Mind-Body Health: Pathways Through the Gut-Brain Axis
07 nov. 2024 11h41 HE | Brain & Behavior Research Foundation
New York, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Intergenerational Effects of Adversity on Mind-Body Health: Pathways...
Logo-InveniAI.png
InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates
20 juil. 2021 08h10 HE | InveniAI LLC
- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...
Photo
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
11 mai 2021 08h10 HE | InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
Logo-InveniAI.png
InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways
09 sept. 2020 08h10 HE | InveniAI
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...